Resumen de Incidence of nephrotoxicity during vancomycin therapy
M.ª Adelina del Olmo Revuelto, Ma. T. Salas Rivera, Rosendo Almendros
Objective: To determine the incidence of nephrotoxicity during vancomycin therapy and study its relationship with different risk factors. Method: A prospective observational study conducted on the total prescribed treatments with vancomycin during six months. We defined nephrotoxicity as a serum creatinine increase of = 0.5 mg/dL or = 50%. Results: The studied population consisted of 50 patients. The mean variance in serum creatinine was 0.036 (CI95%: -0.03 - 0.1) mg/dL. 5/50 (10%) of the patients experienced nephrotoxicity. Associated with age (53.4 vs. 67.6 p = 0.036) and baseline serum creatine values (r = -0.34, p = 0.016). The mean of vancomycin plasma concentrations was 17.3 mg/L (SD = 5.4) and the daily dose 2.4 g/d (SD = 1). Conclusions: (5/50) 10% of the patients met some of the nephrotoxicity criterion. The patients were younger and with lower creatinine levels. They all had average trough concentrations >15 mg/L, with no statistically significant association. None received concurrent treatment with aminoglycosides. The intensive monitoring may have influenced in the lower nephrotoxicity in our study
